辉瑞Tukysa联合疗法3期成功显著延长晚期癌症无进展生存期;三生制药眼科新药申报上市;脱发外用药获1.2亿美元融资

药财社
Oct 16

●药闻快报▲关注药财社聚焦医药界▲1辉瑞Tukysa联合疗法3期成功显著延长晚期癌症无进展生存期辉瑞(Pfizer)日前宣布,其在HER2阳性(HER2+)转移性乳腺癌(MBC)患者中开展的3期HER2CLIMB-05研究获得积极顶线结果。该研究评估患者在接受化疗诱导治疗后,接受酪氨酸激酶抑制剂Tukysa(tucatinib)或安慰剂,与标准一线维持治疗方案(trastuzumab联合...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10